211 related articles for article (PubMed ID: 37712965)
1. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
[TBL] [Abstract][Full Text] [Related]
2. Nucleolin expression has prognostic value in neuroblastoma patients.
Cangelosi D; Brignole C; Bensa V; Tamma R; Malaguti F; Carlini B; Giusto E; Calarco E; Perri P; Ribatti D; Fonseca NA; Moreira JN; Eva A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Pastorino F
EBioMedicine; 2022 Nov; 85():104300. PubMed ID: 36209521
[TBL] [Abstract][Full Text] [Related]
3. Identification of hub genes and their correlation with infiltration of immune cells in
Chen J; Sun M; Chen C; Jiang B; Fang Y
Front Immunol; 2022; 13():1016683. PubMed ID: 36311753
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.
Xia Y; Wang C; Li X; Gao M; Hogg HDJ; Tunthanathip T; Hulsen T; Tian X; Zhao Q
Transl Pediatr; 2024 Jan; 13(1):91-109. PubMed ID: 38323183
[TBL] [Abstract][Full Text] [Related]
6. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
7. Identification of
Shao F; Wang Z; Wang S
DNA Cell Biol; 2021 Feb; 40(2):332-347. PubMed ID: 33393844
[TBL] [Abstract][Full Text] [Related]
8. A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.
Ma K; Zhang P; Xia Y; Dong L; Li Y; Liu L; Liu Y; Wang Y
BMC Med Genomics; 2022 Nov; 15(1):242. PubMed ID: 36419120
[TBL] [Abstract][Full Text] [Related]
9. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
10. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study.
Li M; Duan X; Li C; You D; Liu L
Medicine (Baltimore); 2023 Sep; 102(38):e34925. PubMed ID: 37746942
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel anoikis-related prognostic model and analysis of its correlation with infiltration of immune cells in neuroblastoma.
Chen J; Sun M; Chen C; Kang M; Qian B; Sun J; Ma X; Zhou J; Huang L; Jiang B; Fang Y
Front Immunol; 2023; 14():1135617. PubMed ID: 37081871
[TBL] [Abstract][Full Text] [Related]
13. Identification of prognostic long noncoding RNAs associated with spontaneous regression of neuroblastoma.
Meng X; Fang E; Zhao X; Feng J
Cancer Med; 2020 Jun; 9(11):3800-3815. PubMed ID: 32216054
[TBL] [Abstract][Full Text] [Related]
14. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
15. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
16. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.
Rosswog C; Schmidt R; Oberthuer A; Juraeva D; Brors B; Engesser A; Kahlert Y; Volland R; Bartenhagen C; Simon T; Berthold F; Hero B; Faldum A; Fischer M
Neoplasia; 2017 Dec; 19(12):982-990. PubMed ID: 29091799
[TBL] [Abstract][Full Text] [Related]
17. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance.
Jain D; Somasundaram DB; Aravindan S; Yu Z; Baker A; Esmaeili A; Aravindan N
Cell Biol Toxicol; 2023 Jun; 39(3):967-989. PubMed ID: 34773529
[TBL] [Abstract][Full Text] [Related]
19. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
20. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
